Skye Bioscience (SKYE) Net Income towards Common Stockholders (2012 - 2026)

Skye Bioscience (SKYE) has reported Net Income towards Common Stockholders for 15 consecutive years, with -$10.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 38.8% year-over-year to -$10.8 million in Q2 2026; TTM through Jun 2026 was -$50.5 million, a 19.16% decrease from a year earlier, with the FY2025 full-year figure at -$55.9 million, down 110.5% from the prior year.
• Net Income towards Common Stockholders was -$10.8 million for Q2 2026 at Skye Bioscience, up from -$12.5 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at -$3.0 million in Q1 2022 and troughed at -$24.9 million in Q3 2023.
• A 5-year average of -$9.1 million and a median of -$8.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders tumbled 697.68% in 2023 and jumped 84.37% in 2024, its largest moves.
• Over 5 years, Net Income towards Common Stockholders stood at -$9.9 million in 2022, then surged by 55.32% to -$4.4 million in 2023, then sank by 120.51% to -$9.7 million in 2024, then tumbled by 48.18% to -$14.4 million in 2025, then advanced by 25.31% to -$10.8 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$10.8 million (Q2 2026), -$12.5 million (Q1 2026), and -$14.4 million (Q4 2025), per Business Quant data.